Immunomedics Explained
Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]
History
Immunomedics was founded in July 1982 by David M. Goldenberg.[2]
Michael Pehl was named CEO in December 2017 but left for personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]
In October 2020, Gilead Sciences acquired the company.[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains. [5]
Products
- Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
- Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.[6] In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.[7]
- Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
- Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
- Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.
- IMMU-114 is an anti-HLA-DR for hematological cancers.[8]
Notes and References
- Gilead Sciences Completes Acquisition of Immunomedics, Inc. . . October 23, 2020.
- News: Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder . Adam . Feuerstein . Adam Feuerstein . . January 25, 2017.
- News: Immunomedics CEO Michael Pehl Resigns . Frank . Vinluan . . February 28, 2019.
- Web site: Immunomedics Form 8-K . . February 22, 2019.
- Web site: Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters. 8 March 2022.
- FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments . . April 22, 2020.
- News: Immunomedics, Seattle Genetics Scrap License Deal . ARMIE MARGARET . LEE . . May 5, 2017.
- The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD . X . Chen . C-H . Chang . R . Stein . D M . Goldenberg . . October 24, 2011. 47 . 7 . 967–980 . 10.1038/bmt.2011.203 . 22020022 . 8988947 . free .
